Prolactin and Cortisol Responses to MK-212, a Serotonin Agonist, in Obsessive-Compulsive Disorder

Archives of General Psychiatry

Volumn 47, Issue 9, 1990, Pages 833-839

  Bastani, Bijan ^a   Nash, J Frank ^a   Meltzer, Herbert Y ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; HYDROCORTISONE; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPULSION; HUMAN; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; CLINICAL TRIALS; FEMALE; HUMAN; HYDROCORTISONE; MALE; MIDDLE AGE; OBSESSIVE-COMPULSIVE DISORDER; PROLACTIN; PYRAZINES; RECEPTORS, SEROTONIN; SEROTONIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025184390     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1990.01810210041006     Document Type: Article

References (55)

1. Robins LD, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr, Regier DA. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984;41:949-958.
2. Rasmussen SA, Tsuang MT. The epidemiology of obsessive compulsive disorder. In: Jenike MA, ed. Obsessive-Compulsive Disorder: Theory and Management. Littleton, Mass: PSG Publishing; 1986:23-44.
3. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessivecompulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985;20:1174-1188.
4. Insel TR, Zohar J. Psychopharmacological approaches to obsessive compulsive disorder. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1205-1210.
5. Yaryura-Tobias JA, Neziroglu F. The action of clomipramine in obsessive-compulsive neurosis: a pilot study. Curr Ther Res. 1975;17:111-116.
6. Flament MF, Rapport JL, Berg CJ, Sceery W, Kilts C, Linnoila M. Clomipramine treatment of childhood obsessive compulsive disorder: a doubleblind controlled study. Arch Gen Psychiatry. 1985;42:977-983.
7. Montgomery SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmacol Med. 1980;1:189-192.
8. Marks IM, Stern R, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry. 1980;136:1-25.
9. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder, I: a controlled clinical trial. Arch Gen Psychiatry. 1980;37:1281-1285.
10. Fontaine R, Chouinard G. Fluoxetine in the treatment of obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:605-608.
11. Turner SM, Jacob RG, Beidel DC, Himmelboch J. Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1985;5:207-212.
12. Price LH, Goodman WK, Charney DS, Heninger GR. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry. 1987;144:1059-1061.
13. Kahn RS, Westenberg HMG, Jolles J. Zimelidine treatment of obsessive-compulsive disorder. Acta Psychiatr Scand. 1984;69:259-261.
14. Pasrad A. A double blind study of imipramine versus zimelidine in treatment of obsessive compulsive neurosis. Pharmacopsychiatry. 1984;17:61-62.
15. Yaryura-Tobias JA, Neziroglu F, Bergman L. Clomipramine for obsessive-compulsive neurosis: an organic approach. Curr Ther Res. 1976;20:541-548.
16. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-disorder. Psychiatry Res. 1985;14:83-91.
17. Ananth J, Pecknold JC, van der Steen N, Engelsmann F. Double blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol Biol Psychiatry. 1981;5:257-264.
18. Golden RN, Morris JE, Sack DA. Combined lithium-tricyclic treatment of obsessive-compulsive disorder. Biol Psychiatry. 1983;23:181-185.
19. Rasumussen SA. Lithium and tryptophan augmentation in clomipramine-resistant obsessive compulsive disorder. Am J Psychiatry. 1984;141:1283.
20. Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjoqvist F, Traskman L. Clomipramine treatment of obsessive-compulsive disorder, II: biochemical aspects. Arch Gen Psychiatry. 1980;37:1289-1294.
21. Flament MF, Rapoport JL, Murphy DL, Big CT, Lake CR. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry. 1987;44:219-225.
22. Weizmann A, Carmi M, Hermesh H, Shahar A, Aptar A, Tyano S, Rehavi M. High affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry. 1986;143:335-339.
23. Insel TR, Mueller EA III, Gillin JC, Siever LJ, Murphy DL. Biological markers in obsessive-compulsive and affective disorders. J Psychiatr Res. 1984;18:407-423.
24. Hamik A, Peroutka SJ. 1-(m-Chlorophenyl) piperazine (mCPP) interactions with neurotransmitter receptors in human brain. Biol Psychiatry. 1989;25:569-575.
25. Zohar J, Insel TR. Obsessive-compulsive disorder: psychological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry. 1987;22:667-687.
26. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder: comparisons of patients and healthy controls. Arch Gen Psychiatry. 1987;44:946-951.
27. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL. Serotonergic responsitivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry. 1988;45:167-172.
28. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 1988;45:177-185.
29. Murphy DL, Zohar J, Benkelfat C, Pato MT, Pigott TA, Grover G, Hill IL, Insel TR. Serotonergic agonist and antagonist effects in obsessive-compulsive disorder. Psychopharmacology. 1988;96(suppl):81.
30. Clineschmidt BV. MK-212: a serotonin-like agonist in the CNS. Gen Pharmacology. 1979;10:287-290.
31. Cunningham KA, Callahan PM, Appel JB. Discriminative stimulus properties of the serotonin agonist MK-212. Psychopharmacology. 1986; 90:193-197.
32. Conn PJ, Sanders-Bush E. Relative efficacies of piperazine at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1C) receptors. J Pharmacol Exp Ther. 1987;242:552-557.
33. Koenig JI, Gudelsky GA, Meltzer HY. Stimulation of corticosterone and β-endorphin secretion by selective 5-HT receptor subtype activation. Eur J Pharmacol. 1987;137:1-8.
34. Nash JF, Meltzer HY, Gudelsky GA. Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmacol. 1988;151:463-469.
35. Martin GE, Elgin RJ Jr, Mathiasen JR, Davis CB, Kesslick JM, Baldy WJ, Shank RP, DiStefano DL, Fedde CL, Scott MR. Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989;32:1052-1056.
36. Lowy MT, Meltzer HY. Stimulation of serum cortisol and prolactin secretion in humans by MK-212. Biol Psychiatry. 1988;23:818-828.
37. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry. 1978;35:773-782.
38. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
39. Endicott J, Spitzer RL. Diagnostic interview: Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry. 1987;35:387-444.
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
41. Rachman SJ, Hodgson RJ. Obsessions and Compulsions. Englewood Cliffs, NJ: Prentice-Hall International Inc; 1980.
42. Goodman WK, Price L, Rasmussen SA, Mazure C, Heninger GR, Charney D. Yale-Brown Obsessive Compulsive Scale: validity. In: New research and abstracts of the 141st Annual Meeting of the American Psychiatric Association; May 1988:261, Montreal, Quebec.
43. Meltzer HY, Fleming R, Robertson A. The effect of buspirone on prolactin and growth hormone in man. Arch Gen Psychiatry. 1983;40:1099-1102.
44. Meltzer HY, Umberkoman-Wiita B, Robertson A, Tricou BJ, Lowy M, Perline R. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders, I: enhanced response in depression and mania. Arch Gen Psychiatry. 1984;41:366-374.
45. Meltzer HY. Serotonergic dysfunction in depression. Br J Psychiatry. 1989;155(suppl 8):25-31.
46. Gudelsky GA, Koenig JI, Meltzer HY. Selective desensitization of serotonin (5-HT) receptor-mediated hyperthermia by mianserin and other 5-HT antagonists. Neuropharmacology. 1987;26:707-712.
47. Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K. Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn Schmiedeberg Arch Pharmacol. 1986;332:1-7.
48. Middlemiss DN, Neill J, Tricklebank MD. Subtypes of the 5-HT receptor involved in hypothermia and forepaw treading induced by 8-OH-DPAT. Br J Pharmacology. 1985;85:251P.
49. Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. J Receptor Res. 1988;8:59-81.
50. Glennon RA, Ishmaaid AEM, McCarthy BB, Perontha SJ. Binding of arylpeperazines to 5-HT3 serotonin receptors: results of a structure-activity study. Eur J Pharmacol. 1989;168:381-392.
51. Heninger GR, Charney DS, Smith A. Effects of serotonin receptor agonists and antagonists on neuroendocrine function in rhesus monkeys. Soc Neurosci Abstr. 1987;13:574.
52. Meltzer HY, Nash JR Jr. Serotonin and mood: neuroendocrine aspects. In: Granten D, Pfaff D, eds. Current Topics in Neuroendocrinology. Heidelberg, Germany: Springer-Verlag; 1988;8:183-210.
53. Charig EM, Anderson IM, Robinson Sen JM, Nutt DJ, Cowen PJ. L-Tryptophan and prolactin release: evidence for interaction between 5-HT, and 5-HT22 receptors. Hum Psychopharmacol. 1986;1:93-97.
54. Lee MA, Nash JF, Barnes M, Meltzer HY. Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol and prolactin secretion in humans. Psychopharmacology. In press.
55. Hollander E, Fay M, Cohen B, Campeas J, Gorman JM, Liebowitz MR. Serotonergic and noradrenergic sensitivity in obsessive compulsive disorder: behavioral findings. Am J Psychiatry. 1988;145:1015-1017.